CliffBio
small molecule

ABREVA

DOCOSANOL

Loss of exclusivity—loss of exclusivity
CompanyHaleon →See this company's full patent-cliff portfolio

Drug detail

Brand nameABREVA
Active ingredientDOCOSANOL
Strength10%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2000
Marketing statusOTC

More from Haleon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.